Currently Viewing:
Newsroom
Currently Reading
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
January 20, 2018 – Laura Joszt
Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access
January 19, 2018 – Mary Caffrey
Long-Term Oral Contraceptive Use Associated With Reduced Risk of Ovarian, Endometrial Cancer
January 19, 2018 – Jaime Rosenberg
This Week in Managed Care: January 19, 2018
January 19, 2018
Wearable Biosensors Have No Significant Impact on Clinical Outcomes
January 19, 2018 – Kaitlynn Ely
Proposed Drug to Treat Oculopharyngeal Muscular Dystrophy Gains Orphan Drug Designation
January 19, 2018 – Kelly Davio
What We're Reading: House Passes CHIP Funding; Cancer Blood Test; Drug Policy Office Budget
January 19, 2018 – AJMC Staff
AJMC® in the Press, January 19, 2018
January 19, 2018 – AJMC Staff
Risk-Targeted Lung Cancer Screening Shows Modest Benefits
January 19, 2018 – Samantha DiGrande

Active Surveillance Economical Over Immediate Treatment for Low-Risk Prostate Cancer

Researchers in Canada have developed a model to simulate the cost of active surveillance versus immediate treatment among low-risk prostate cancer patients.

Active surveillance for low-risk prostate cancer in Canada could save nearly $100 million annually without worsening quality-adjusted life expectancy (QALE), according to results of a simulation comparing active surveillance with immediate treatment.

Many prostate cancers, especially those in the low-risk category, are indolent and may not require immediate treatment. At least one study has showed that QALE is greater for active surveillance than for brachytherapy, intensity-modulated radiotherapy, or radical prostatectomy.

Still, despite published guideline recommendations, as many as 90% of men with prostate cancer receive immediate treatment. Such overtreatment can be a tremendous financial burden to healthcare systems.

To see how costly it might be, Dr. Alice Dragomir and colleagues from McGill University in Montreal developed a Markov model with Monte Carlo microsimulations to estimate the direct cost associated with active surveillance and immediate treatment for low-risk prostate in Canada.

Then, they compared Canadian and US cost estimates, and published their findings online April 24th in CMAJ Open.

Source: Medscape

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!